Dr. Sabbatini on the Future of Dose-Dense Therapy in Ovarian Cancer

Paul Sabbatini, MD
Published Online: Thursday, Nov 09, 2017



Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses the future of dose-dense therapy in ovarian cancer.

Dose-dense therapy or every-3-week therapy can now be used in several additional combinations in the primary therapy setting. A variety of combinations and strategies are being attempted, which can be difficult to do with intraperitoneal (IP) chemotherapy, explains Sabbatini.

IP chemotherapy is traditionally used to treat patients with ovarian cancer and can treat other gynecologic malignancies, except endometrial or cervical cancers, says Sabbatini.


Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses the future of dose-dense therapy in ovarian cancer.

Dose-dense therapy or every-3-week therapy can now be used in several additional combinations in the primary therapy setting. A variety of combinations and strategies are being attempted, which can be difficult to do with intraperitoneal (IP) chemotherapy, explains Sabbatini.

IP chemotherapy is traditionally used to treat patients with ovarian cancer and can treat other gynecologic malignancies, except endometrial or cervical cancers, says Sabbatini.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x